Chimeric Therapeutics Limited (ASX:CHM)

Market Cap	11.05M
Revenue (ttm)	12.68M +70.1%
Net Income	-10.43M
EPS	-0.01
Shares Out	4.42B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,055,500
Average Volume	3,981,511
Open	0.0020
Previous Close	0.0025
Day's Range	0.0020 - 0.0020
52-Week Range	0.0020 - 0.0090
Beta	1.48
RSI	43.39
Earnings Date	Feb 27, 2026

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CHM

Financial Performance

In fiscal year 2025, Chimeric Therapeutics's revenue was 12.68 million, an increase of 70.09% compared to the previous year's 7.46 million. Losses were -10.43 million, -16.76% less than in 2024.